Current Report Filing (8-k)

Date : 05/16/2019 @ 10:22PM
Source : Edgar (US Regulatory)
Stock : Iovance Biotherapeutics, Inc. (IOVA)
Quote : 21.95  2.85 (14.92%) @ 12:28AM

Current Report Filing (8-k)

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K
Current Report

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): May 15, 2019

 

IOVANCE BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)

 

Delaware
(State of Incorporation)
 
001-36860   75-3254381
Commission File Number   (I.R.S. Employer Identification No.)
     
999 Skyway Road, Suite 150    
San Carlos, California   94070
(Address of Principal Executive Offices)   (Zip Code)
     
(650) 260-7120
(Registrant’s Telephone Number, Including Area Code)
 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

  

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.000041666 per share IOVA The Nasdaq Stock Market, LLC

 

 

 

 

 

  

Item 8.01. Other Events.

 

On May 15, 2019, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing updates from ongoing clinical trials including new interim data from studies of tumor infiltrating lymphocyte (“TIL”) therapy LN-145 in patients with advanced cervical cancer and with TIL therapy lifileucel in advanced melanoma. In addition, the Company announced that the first PD-1/PD-L1 naive patient has been dosed with TIL therapy and that it has entered into a collaboration with Genocea Biosciences, Inc., to evaluate the potential for an improved TIL product. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

On May 15, 2019, the Company also updated its corporate presentation that it uses for presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the Company’s presentation that it intends to use at such events is attached as Exhibit 99.2 and incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)       Exhibits

 

Exhibit No.   Description
99.1   Press Release dated May 15, 2019.
99.2   Iovance Biotherapeutics, Inc., Corporate Presentation - May 2019.

 

 

 

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: May 16, 2019 IOVANCE BIOTHERAPEUTICS, INC.  
       
       
  By: /s/ MARIA FARDIS  
    Maria Fardis, Chief Executive Officer  
       

 

 

 

 

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Historical Stock Chart

1 Year : From Jun 2018 to Jun 2019

Click Here for more Iovance Biotherapeutics, Inc. Charts.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Intraday Stock Chart

Today : Monday 17 June 2019

Click Here for more Iovance Biotherapeutics, Inc. Charts.

Latest IOVA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.